Using flow cytometry analyses, we observed that the CTLA-4 mAb led to a marked reduction in CD4+CD25+FoxP3+ Tregs in melanoma, consistent with early studies (Supplementary Fig. 3i, m). Here, CTLA4 is linked to melanoma.